ArticleFrontiers in immunology2025
Novel insights into ORFV B2L DNA vaccine-mediated gut microbiota modulation and immune augmentation in rats.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expression of Orf Virus B2L Protein and Monoclonal Antibody Preparation.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Orf virus (ORFV) poses a significant threat to livestock and human health, causing economic losses in the livestock industry and potential zoonotic infections. Given the limitations of current vaccines, the objective of this study was to investigate the immune response and gut microbiota modulation induced by the ORFV B2L gene-based DNA vaccine (GV) and the live attenuated vaccine (LV) in rats. The findings of this study will provide a scientific foundation for the development of more effective vaccines. Female Sprague-Dawley rats, which were free of specific pathogens, were divided into three groups. The experiment included three groups: the first group was designated as the GV group, the second group was designated as the LV group, and the third group was designated as the control group. Rats in the GV group received intra-muscular injection of 100μg/dose of pVAX - B2L - asd plasmid, those in the LV group were immunized with a commercial live - attenuated vaccine, and the control group was injected with PBS. After immunization, various immune - related parameters, such as T - cell subsets, antibody levels, cytokines, and oxidative stress markers, were measured. To this end, composition and function of gut microbiota were thoroughly examined through the implementation of 16S rRNA gene sequencing and PICRUSt-2 functional prediction. The GV group exhibited elevated levels of cellular and humoral immunity. It had a higher percentage of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.